Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA approved it to prevent blood clots in acutely ill medical patients. The drug, marketed by ...

Factor XI, it turns out, is crucial for the formation of the bad clots inside blood ... over drugs called factor Xa ...

Specifically, this medication is taken to prevent DVT ... of as a group of small cells sticking together that form blood clots. Xarelto decreases the production of thrombin, another molecule ...

Prices were also negotiated for Janssen’s blood clot medication Xarelto, Novartis’s heart failure drug Entresto and Pharmacyclics blood cancer drug Imbruvica. When negotiating the maximum fair ...

Bayer has started proof-of-concept testing of a potential new therapy for patients with deep vein thrombosis (DVT) that works in a different way to current drugs ... when a blood clot forms ...

The group has seen recent successes in battling these lawsuits. The exclusivity for Bayer’s blood-clot medication, Xarelto, its bestselling drug, is set to expire in 2026, allowing competitors ...